Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma

Experimental Biology and Medicine

Volumn 234, Issue 7, 2009, Pages 726-736

  Feo, Francesco ^a   Frau, Maddalena ^a   Tomasi, Maria L ^a   Brozzetti, Stefania ^b   Pascale, Rosa M ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cell cycle; Genetic predisposition; Hepatocarcinogenesis; Signaling pathways

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE;

BIOLOGICAL THERAPY; CANCER SUSCEPTIBILITY; CELL CYCLE; CHEMOPROPHYLAXIS; EPIGENETICS; GENE; GENE MUTATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MODEL; NONHUMAN; PROGNOSIS; SHORT SURVEY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; RATS; RATS, INBRED BN; RATS, INBRED F344; SIGNAL TRANSDUCTION;

RATTUS; RODENTIA;

EID: 67650224486     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0901-MR-40     Document Type: Short Survey

References (64)

1. Bruix J, Boix L, Sala M, Llovet, JM. Focus on hepatocellular carcinoma. Cancer Cell 5:215-219, 2004.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339-346, 2002.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-678, 2006.
4. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. A comparison of the molecular clock of hepatitis C virus in United States and Japan predicts that hepatocellular carcinoma incidence in United States will increase over the next two decades. Proc Natl Acad Sci U S A 99:15584-15589, 2002.
5. Sell S. Cellular origin of hepatocellular carcinoma. Cell Dev Biol 13:419-424, 2002.
6. Su Q, Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol 31:126-133, 2003.
7. Farber E, Sarma DSR. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 56:4-22, 1987.
8. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. In: Vance Woude GF, Kelin G, Eds. Advances in Cancer Research. New York: Academic Press, Vol 86: pp70-111, 2002.
9. Feo F, Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF. Genetic alterations in liver carcinogenesis. Crit Rev Oncog 11:19-62, 2000.
10. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, Pascale RM. Hepatocellular carcinoma as a complex polygenic disease. Interpretative analysis of recent developments on genetic predisposition. BBA Cancer Rev 1765:126-147, 2006.
11. Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 9:2428-2432, 2003.
12. Dragani TA, Manenti G, Della Porta G. Genetic susceptibility to murine hepatocarcinogenesis is associated with high growth rate of NDEA-initiated hepatocytes. J Cancer Res Clin Oncol 113:223-229, 1987.
13. Dragani TA, Manenti G, Gariboldi M, De Gregorio L, Pierotti MA. Genetics of liver tumor susceptibility in mice. Toxicol Lett 82-83:613-619, 1995.
14. Bilger A, Bennet LM, Carabeo RA, Chiaverott TA, Dvorak C, Liss KM, Schadewald SA, Pitot HC, Drinkwater NR. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 167:859-866, 2004.
15. Poole TM, Drinkwater NR. Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones. Proc Natl Acad Sci U S A 93:5848-5853, 1996.
16. Lee GH, Drinkwater NR. The Hcr (hepatocarcinogen resistance) loci of DBA/2J mice partially suppress phenotypic expression of the Hcs (hepatocarcinogen sensitivity) loci of C3H/HeJ mice. Carcinogenesis 161:1993-1996, 1995.
17. Manenti G, Galvan A, Favella FS, Pascale RM, Spada E, Dilani S, Neira AG, Feo F, Dragani TA. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 48:617-623, 2008.
18. Melhem MF, Kunz HW, Gill TJ III. A major histocompatibility complex-linked locus in the rat critically influences resistance to diethylnitrosamine carcinogenesis. Proc Natl Acad Sci U S A 90:1967-1971, 1993.
19. De Miglio MR, Canzian F, Pascale RM, Simile MM, Muroni MR, Calvisi DF, Romeo G, Feo F. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res 59:4651-4657, 1999.
20. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Calvisi DF, Virdis P, Bosinco GM, Frau M, Seddaiu MA, Ladu S, Feo F. Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis. Cancer Res 62:4459-4463, 2002.
21. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Virdis P, Kwong KM-T, Wong LKL, Bosinco GM, Pulina FR, Calvisi DF, Frau M, Wood GA, Archer MC, Feo F. Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats. Int J Cancer 111:9-16, 2004.
22. Zeng ZZ, Higashi S, Kitayama W, Denda A, Yan Y, Matsuo K, Konishi Y, Hiai H, Higashi K. Genetic resistance to chemical carcinogen-induced preneoplastic hepatic lesions in DRH strain rats. Cancer Res 60:2876-2881, 2000.
23. Liu H, Higashi K, Hiai H. Role of resistant Drh1 locus in chemical carcinogen-induced hepatocarcinogenesis in rats: analysis with a speed congenic strain. Cancer Sci 9:164-169, 2005.
24. De Miglio MR, Virdis P, Calvisi DF, Frau M, Muroni MR, Simile MM, Daino L, Careddu G, Sanna-Passino E, Pascale RM, Feo F. Mapping a sex-hormone sensitive gene determining female resistance to liver carcinogenesis in a congenic F344.BN-Hcs4 rat. Cancer Res 66:10384-10390, 2006.
25. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387:365-372, 2006.
26. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349:431-434, 1991.
27. Simile MM, Pagnan G, Pastorino F, Brignole C, De Miglio MR, Muroni MR, Asara G, Frau M, Seddaiu MA, Calvisi DF, Feo F, Ponzoni M, Pascale RM. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-fkappagB and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 26:417-422, 2005.
28. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, De Miglio MR, Frau M, Tomasi ML, Seddaiu MA, Daino L, Virdis P, Feo F, Pascale RM. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for human disease. Carcinogenesis 29:1639-1647, 2008.
29. Arsura M, Cavin LG. Nuclear factor-kB and liver carcinogenesis. Cancer Lett 229:157-169, 2005.
30. Hussain PS, Hofset LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 3:276-285, 2003.
31. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 410:37-40, 2001.
32. Calvisi DF, Pascale RM, Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2:217-236, 2007.
33. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39:741-749, 2007.
34. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150-157, 2005.
35. Alexia C, Fourmatgeat P, Delautier D, Groyer A. Insulin-like growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI-3′K/Akt signaling. Exp Cell Res 312:1142-1152, 2006.
36. Factor V, Oliver AL, Panta GR, Thorgeirsson SS, Sonenshein GE, Arsura M. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology 34:32-41, 2001.
37. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 67:2736-2746, 2007.
38. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Sanna V, Sini M, Daino L, Simile MM, De Miglio MR, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM. Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. Int J Cancer 123:2057-2064, 2008.
39. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM. Dual-Specificity phosphatase 1 ubiquitination in extracellular signal-regulated-kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 68:4192-4200, 2008.
40. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, De Miglio MR, Tomasi ML, Sanna V, Muroni MR, Feo F, Pascale RM. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2008, in press.
41. Costa RH, Kalinichenko VV, Major ML, Raychaudhuri P. New and unexpected: forkhead meets ARF. Curr Opin Genet Dev 15:42-48, 2005.
42. Wierstra I, Alves J. FOXM1, a typical proliferation associated transcription factor. Biol Chem 388:1257-1274, 2007.
43. Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A 99:16881-16886, 2002.
44. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830-850, 2004.
45. Nasi S, Ciarapica R, Jucker R, Rosati J, Souceck L. Making decisions through Myc. FEBS Lett 490:153-162, 2001.
46. Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G, Casabona D, Frau M, Seddaiu MA, Feo F. Differences in cell cycle deregulation in neoplastic liver lesions of rats with and without genetic predisposition to hepatic carcinogenesis. Hepatology 15:1341-1350, 2002.
47. Adams PD. Regulation of retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471:123-133, 2001.
48. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 20:4462-4473, 2000.
49. Gaubatz S, Lees JA, Lindeman GJ, Livingston DM. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol Cell Biol 21:1384-1392, 2001.
50. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 42:1310-1319, 2005.
51. Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 52:2071s-2077s, 1992.
52. Garcea R, Daino L, Pascale RM, Simile MM, Puddu M, Ruggin ME, Seddaiu MA, Satta G, Sequenza MJ, Feo F. Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine: S-adenosylhomocysteine ratio. Carcinogenesis 10:1183-1192, 1989.
53. Rao PM, Antony A, Rajalakshmi S, Sarma DS. Studies on hypomethylation of liver DNA during early stages of chemical carcinogenesis in rat liver. Carcinogenesis 10:933-937, 1989.
54. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 16:15-26, 2002.
55. Torres L, Avila MA, Carretero MV, Latasa MU, Caballería J, López-Rodas G, Boukaba A, Lu SC, Franco L, Mato JM. Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation. FASEB J 14:95-102, 2000.
56. Yang H, Huang ZZ, Zeng Z, Chen C, Selby RR, Lu SC. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am J Physiol Gastrointest Liver Physiol 280:G184-190, 2001.
57. Torres L, Lopez-Rodas G, Latasa MU, Carretero MV, Boukaba A, Rodriguez JL, Luis Franco L, Mato JM, Avila MA. DNA methylation and histone acetylation of rat methionine adenosyltransferase 1A and 2A genes is tissue-specific. Int J Biochem Cell Biol 32:397-404, 2000.
58. Ikeda R, Nishida T, Watanabe F, Shimizu-Saito K, Asahina K, Horikawa S, Teraoka H. Involvement of CCAAT/enhancer binding protein-beta (C/EBPbeta) in epigenetic regulation of mouse methionine adenosyltransferase 1A gene expression. Int J Biochem Cell Biol 40:1956-1969, 2008.
59. Calvisi DF, Simile MM, Ladu S, Pellegrino R, De Murtas V, Pinna F, Tomasi ML, Frau M, Virdis P, De Miglio MR, Muroni MR, Pascale RM, Feo F. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int J Cancer 121:2410-2420, 2007.
60. Majano PL, Garcia-Monzon C, García-Trevijano ER, Corrales FJ, Camara J, Ortiz P, Mato JM, Avila MA, Moreno-Otero R. S-adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J Hepatol 35:692-699, 2001.
61. Lim S-O, Gu JM, Kim MS, Kim H-S, Park YN, Park CK, Cho JW, Park YM, Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135:2128-2140, 2008.
62. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327, 2008.
63. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3:209-212, 1994.
64. Hemminki K, Li X. Familial risks of cancer as a guide to gene identification and mode of inheritance. Int J Cancer 110:291-294, 2004.